进行性核上性麻痹睡眠障碍的治疗:比较唑吡坦、苏沃雷生与安慰剂的随机、远程、双盲、6周交叉设计研究方案
该研究方案为一项远程、随机、双盲、6周交叉临床试验,受试者在安慰剂、15 mg/日苏沃雷生和5 mg/日唑吡坦三种方案中按随机平衡顺序接受干预,各阶段间隔1周洗脱。研究旨在评估靶向促觉醒系统的食欲素拮抗剂苏沃雷生与靶向促睡眠系统的GABA能受体激动剂唑吡坦及安慰剂在治疗进行性核上性麻痹睡眠/觉醒问题中的安全性和有效性。
要点
- 进行性核上性麻痹患者存在显著睡眠破坏,下丘脑和脑干等睡眠/觉醒调节区域早期受累。
- 研究假设食欲素拮抗剂苏沃雷生可能比其他催眠药物更有效治疗进行性核上性麻痹的睡眠/觉醒问题。
- 该远程交叉试验比较安慰剂、15 mg/日苏沃雷生和5 mg/日唑吡坦的安全性和有效性。
核心结论
- 研究旨在检验食欲素拮抗剂苏沃雷生靶向促觉醒系统与GABA能受体激动剂唑吡坦靶向促睡眠系统及安慰剂相比,治疗进行性核上性麻痹睡眠/觉醒问题的安全性和有效性。
研究设计与样本
- 这是一项远程临床试验,设计为双盲、交叉、受试者内6周试验,包含3个为期1周的干预阶段,阶段间设1周洗脱期。
- 3种方案的顺序随机且平衡:安慰剂(微晶纤维素)、15 mg/日苏沃雷生、5 mg/日唑吡坦。
- 受试者通过医生和研究转诊、登记库及支持团体招募;评估包括神经科访谈、认知测试和主观问卷包。
- 通过受试者全程佩戴的动态脑电图和体动记录仪监测设备评估睡眠和昼夜节律。
主要发现
- 既往研究在进行性核上性麻痹中识别出显著睡眠破坏,下丘脑和脑干等调节睡眠/觉醒模式的区域是疾病进展中最早受累的脑区之一。
- 比较多导睡眠图和定量神经病理学指标发现,与阿尔茨海默病相比,进行性核上性麻痹中促觉醒核团相对保留,但睡眠破坏更严重;无论何种疾病,促觉醒核团神经元计数越高与夜间觉醒越多相关。
- 外侧下丘脑的食欲素能促觉醒神经元在进行性核上性麻痹中相对保留,该区域先前被描述为睡眠开/关开关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 为罕见病实施远程临床试验会产生面对面研究中不存在的独特问题。
- 当潜在疾病修饰疗法可用时,针对症状而非疾病修饰的试验招募具有挑战性。
- 需要与非关联医疗办公室协调获取医疗记录或处方,可能给潜在受试者、医疗办公室和研究团队带来困扰。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prior research identified profound sleep disruption in progressive supranuclear palsy (PSP). The hypothalamus and brainstem, areas that help regulate sleep/wake patterns, are among the earliest affected brain regions in PSP disease progression. Comparing polysomnography and quantitative-neuropathology metrics, we identified relative sparing of wake-promoting nuclei in PSP compared to Alzheimer's disease, though PSP had more disrupted sleep. It led to the hypothesis that PSP patients have hyperinsomnia (or hyposomnia, little sleep) due to degeneration of sleep nuclei with a preservation of sleep neurons, causing a system unbalance. A higher neuronal count of wake-promoting nuclei was associated with greater nocturnal wake, regardless of disease. Specifically, orexinergic wake-promoting neurons in the lateral hypothalamus, previously described as the sleep-on/off switch, are relatively spared in PSP. Thus, we hypothesized that an orexinergic antagonist may be more effective in treating sleep/wake issues in PSP than other hypnotic medications. This study protocol was established to test the safety and efficacy of an orexinergic antagonist (suvorexant) targeting the wake-promoting system and contrasts it with a GABAergic receptor agonist (zolpidem) targeting sleep-promoting systems and placebo. METHODS: This is a remote clinical trial, designed as a double-blind, cross-over, within-subject 6-week trial, with 3 one-week-long conditions, separated by 1-week washout periods. The order of the 3 regimens is randomized and counterbalanced: placebo (microcrystalline cellulose), 15 mg/day suvorexant, 5 mg/day zolpidem. Participants are recruited from doctor and study referrals, registries, and support groups. Once onboarded, the trial coordinator maintains communication with the participant/caregiver throughout the 6 weeks. Assessments include neurological interviews, cognitive testing, and subjective questionnaire packets. Sleep and circadian rhythms are assessed through ambulatory EEG and actigraphy monitoring devices worn by the participant throughout the trial. DISCUSSION: The study design aims to reduce participant and caregiver burden, while improving accessibility to such a study. Administering a remote clinical trial for a rare disease, however, creates unique issues that would otherwise be absent from in-person studies. Particularly, a symptom rather than disease-modifying trial is challenging to recruit for when potential disease-modifying therapeutics are available. Needing to coordinate with non-associated medical offices to attain medical records or prescriptions can cause frustrations for the potential participant, medical office, and study team. In recruitment, onboarding, and trial maintenance, this study design relies on consistent communication to support participant enrollment and satisfaction. TRIAL REGISTRATION: Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP); NCT04014389. Registered on June 2, 2019.
引用
- Li E, Song F, Coppola Q, et al. Treatment of Disturbed Sleep in Progressive Supranuclear Palsy: a randomized, remote, double-blinded, 6-week cross-over design study protocol comparing zolpidem, suvorexant, and placebo. Trials. 2026. PMID: 41501928. doi:10.1186/s13063-025-09382-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。